Bruce Eaton

Bruce currently serves as the Chairman of Velocity Sciences and as the Executive Vice President and Chief Business Officer of Editas Medicine. At Editas, Bruce oversees the Company’s business development, alliance management, and strategy initiatives. Bruce has more than 30 years of experience in science, operations, business development, and corporate strategy in both public and private companies. He has a deep understanding of biotechnology and in driving innovation and development across multiple disciplines in life sciences, including diagnostics and therapeutics. He has served in C-level and director-level roles at multiple companies and acted as an advisor to numerous government and academic research institutions.

Bruce was the founding CEO of Velocity Sciences and i2 Pharmaceuticals, where both companies were formed to leverage his extensive knowledge of oligonucleotide chemistry. He joined Editas in January 2018 as part of the acquisition of assets from i2 Pharmaceuticals. Prior to i2, Bruce was Chief Operating Officer of SomaLogic, where he was responsible for operations, business development, and corporate strategy. Earlier in his career, Bruce also served as Vice President of NexaGen and was part of the team responsible for the merger with Vestar to create NexStar where he built and lead the groups responsible for GMP synthesis and analytics for the drug Macugen as well as the research and process development efforts to support the liposomal delivery technology of the drug Ambisome.

Bruce received his Ph.D. in chemistry from the University of California at Berkeley and his B.S. degrees in chemistry and biology from the University of Oregon.